FY2025 · ended Oct 31, 2025 · Revenue $9.00M, -5.3% YoY · Filed Jan 29, 2026
Pharma-Bio Serv, Inc. (PBSV) files with the SEC under industry code 8742, Services-Management Consulting Services. In fiscal 2025, which ended Oct 31, 2025, it reported revenue of $9.0 million and a net loss of $100,463. Free cash flow was -$221,530. As of Jul 31, 2026 it held $8.6 million in cash and investments and $0 in total debt.
Revenue (TTM)
$9.48M
+3.3% vs year-ago TTM
Net income (TTM)
$251,525
+398.5% vs year-ago TTM
Operating cash flow (TTM)
$-414,892
+0.3% vs year-ago TTM
Free cash flow (TTM)
$-421,364
+27.3% vs year-ago TTM
EPS (TTM)
$0.01
+399.0% vs year-ago TTM
Dividend per share
$0.07
Shares outstanding
22.90M
+0.0% vs prior year
Net cash
$8.58M
as of Jul 31, 2026
Operating margin
-1.6%
FY 2026
Company profile
- Industry
- Services-Management Consulting Services (SIC 8742)
- Listed as
- PBSV (OTC)
- Fiscal year ends
- October 31
- Headquarters
- Dorado, PR
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1304161
- Former names
- LAWRENCE CONSULTING GROUP INC (until Feb 28, 2006)
Other Services-Management Consulting Services companies
- Cgi Inc GIB
- Booz Allen Hamilton Holding Corp BAH
- Genpact LTD G
- Fti Consulting, Inc FCN
- Exponent Inc EXPO
- Huron Consulting Group Inc. HURN
- Astrana Health, Inc. ASTH
- ICF International, Inc. ICFI
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Oct 31, 2025 |
FY 2024 Oct 31, 2024 |
FY 2023 Oct 31, 2023 |
FY 2022 Oct 31, 2022 |
FY 2021 Oct 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.0M | $9.5M | $17.0M | $19.4M | $20.1M |
| Operating income | -$637,662 | -$1.3M | $1.1M | $1.2M | -$3.9M |
| Net income | -$100,463 | -$777,619 | $1.3M | $1.0M | -$2.1M |
| Diluted EPS | -$0.00 | -$0.03 | — | — | — |
| Operating cash flow | -$214,886 | -$566,701 | $1.9M | $592,457 | $804,842 |
| Free cash flow | -$221,530 | -$726,444 | $1.9M | $573,188 | $793,997 |
| Total assets | $13.7M | $16.3M | $19.9M | $20.7M | $23.9M |
| Total liabilities | $1.7M | $2.6M | $3.8M | $4.1M | $5.0M |
| Stockholders' equity | $11.9M | $13.7M | $16.1M | $16.6M | $18.9M |
| Cash and investments | $10.9M | $12.7M | $15.0M | $14.5M | $17.5M |
| Total debt | $28,834 | $194,035 | $346,509 | $487,364 | $617,424 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Sep 14, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Results of operations
|
Jun 15, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | Jun 15, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 15, 2026 | May 15, 2026 |
| ARS | Annual report to shareholders | Apr 16, 2026 | Oct 31, 2025 |
All 527 Pharma-Bio Serv, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.